Effects of a single local administration of cilostazol on neointimal formation in balloon-injured rat carotid artery

Atherosclerosis

Volumn 142, Issue 1, 1999, Pages 41-46

  Ishizaka, Nobukazu ^a   Taguchi, Junichi ^a   Kimura, Yukio ^b   Ikari, Yuji ^a   Aizawa, Toru ^a   Togo, Masako ^a   Miki, Keizaburoh ^c   Kurokawa, Kiyoshi ^a   Ohno, Minoru ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^c TERUMO CORPORATION   (Japan)

Author keywords

Balloon injury; Cilostazol; Cyclic AMP; Neointima

Indexed keywords

BROXURIDINE; CILOSTAZOL; PHOSPHODIESTERASE INHIBITOR;

ANIMAL CELL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; BALLOON CATHETER; CAROTID ARTERY DISEASE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RESTENOSIS; SMOOTH MUSCLE FIBER; TOPICAL DRUG ADMINISTRATION;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADMINISTRATION, TOPICAL; ANGIOPLASTY, BALLOON; ANIMALS; ARTERIAL OCCLUSIVE DISEASES; CAROTID ARTERIES; CELL DIVISION; MALE; MUSCLE, SMOOTH, VASCULAR; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, WISTAR; RECURRENCE; TETRAZOLES; TUNICA INTIMA;

EID: 0032890246     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00147-6     Document Type: Article

References (30)

1. Holmes D.R., Vliestra R.E., Smith H.C., Vetrovec G.W., Kent K.M., Cowley M.J., Faxon D.P., Gruentzig A.R., Kelsey S.F., Detre K.M., Van Raden M.J., Molk M.B. Restenosis after percutaneous transluminal coronary angioplasty. A report from the PTCA registry of the National Heart, Lung, and Blood Institute. Am. J. Cardiol. 53:1994;77C.
2. White C.W., Chaitman B., Lassar T.A., Marcus M.L., Chisholm R.J., Knudson M. Antiplatelet agents are effective in reducing the immediate complications of PTCA; results from the ticlopidine multicenter trial (abstract). Circulation. 76(Suppl. IV):1987;400.
3. Schwartz L., Bourassa M.G., Lesperanc J., Aleridge H.E., Kazim F., Salvatori V.A. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N. Engl. J. Med. 318:1988;1714.
4. Barnathan E.S., Schwartz J.S., Taylor L., Laskey W.K., Klearsland J.P., Kussmaul W.G. Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation. 76:1987;125.
5. Topol E.J., Califf R.M., Weisman H.F., Ellis S.G., Tcheng J.E., Worley S., Ivanhoe R., George B.S., Fintel D., Weston M., Sigmon K., Anderson K.M., Lee K.L., Willerson J.T. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet. 343:1994;881.
6. Fingerle J., Johnson R., Clowes A.W., Majesky M.W., Reidy M.A. Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery. Proc. Natl. Acad. Sci. 86:1989;8412.
7. Wolfgang V., Verona F. Aspirin reduces the growth of medial and neointimal thickening in balloon-injured carotid arteries. Stroke. 21(Suppl. IV):1990;44.
8. Powell J.S., Muller R.K.M., Baumgartner H.R. Suppression of the vascular response to injury: the role of angiotensin-converting enzyme inhibitors. J. Am. Coll. Cardiol. 17:1991;137B.
9. Tani T., Watanabe K., Matsumoto Y., Ikezono K., Yoshikawa T., Kimura Y., Kubota Y., Uchida H. Effectiveness of cilostazol on vascular intimal hyperplasia induced by endothelial denudation in the rat and by stent placement in the dog. Thromb. Haemostas. 69:1993;808. Abstract.
10. Kimura Y., Tani T., Kanbe T., Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforshung. 35(II):1985;1144.
11. Kamakura K., Watanabe K., Kimura K. Effect of cilostazol, a new antithrombotic drug, on cerebral circulation. Arzneimittelforshung. 35(II):1985;1149.
12. Inoue Y., Kimura Y., Hidaka H. Role of platelet in vascular intimal hyperplasia. Jpn. J. Thromb. Hemost. 4:1993;297. Abstract.
13. Taguchi J., Abe J., Ohno M., Kurokawa K. L-Arginine inhibits neointimal formation following balloon injury. Life Sci. 53:1993;PL387.
14. Taguchi J., Abe J., Ohno M., Kurokawa K. Angiotensin converting enzyme inhibitors or DuP753 prevent neointimal formation following balloon injury with single topical or multiple systemic application. Biochem. Biophys. Res. Commun. 196:1993;969.
15. Abe J., Zhou W., Taguchi J., Kurokawa K., Takuwa Y. Suppression of neointimal smooth muscle cell accumulation in vivo by antisense CDC2 and CDK2 oligonucleotides in rat carotid artery. Biochem. Biophys. Res. Commun. 198:1994;16.
16. Akiyama H., Kudo S., Shimizu T. The absorption, distribution and excretion of a new antithrombotic and vasodilating agent, cilostazol, in rat, rabbit, dog and man. Arzneimittelforshung. 35:1985;1124.
17. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362(1993):1990;801.
18. Vemulapalli S., Chiu P.J., Kurowski S., Brown A., Hartman B.D., Leach M.W. In vivo inhibition of platelet adhesion by a cGMP-mediated mechanism in balloon catheter injured rat carotid artery. Pharmacology. 52:1996;235.
19. Takahashi S., Oida K., Fujiwara R., Maeda H, Harashi S., Takai S., Tamai T., Nakai T., Miyabo S. Effect of cilostazol, novel AMP phophodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J. Cardiovasc. Pharmacol. 20:1992;900.
20. Bennett M.R., Littlewood T.D., Hancock D.C., Evan G.I., Newby A.C. Down-regulation of the c-myc proto-oncogene in inhibition of vascular smooth-muscle cell proliferation: a signal for growth arrest? Biochem. J. 302:1994;701.
21. Cook S.J., McCormick F. Inhibition by cAMP of Ras-dependent activation of Raf. Science. 262:1993;1069.
22. Grieco D., Porcellini A., Avvedimento E.V., Gottesman M.E. Requirement for cAMP-PKA pathway activation by M phase-promoting factor in the transition from mitosis to interphase. Science. 271:1996;1718.
23. Kayanoki Y., Che W., Kawata S., Matsuzawa Y., Higashiyama S., Taniguchi N. The effect of cilostazol, a cyclic nucleotide phosphodiesterase III inhibitor, on heparin-binding EGF-like growth factor expression in macrophages and vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 238:1997;478.
24. Simons M., Edelman E.R., DeKeyser J.L., Langer R., Rosenberg R.D. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature. 359:1992;67.
25. Tanaka T., Ishikawa T., Hagiwara M., Onoda K., Itoh H., Hidaka H. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology. 36:1988;313.
26. Take S., Matsutani M., Ueda H., Hamaguchi H., Konishi H., Baba Y., Kawaratani H., Sugiura T., Iwasaka T., Inada M. Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty. Am. J. Cardiol. 79:1997;1097.
27. Ochiai M., Isshiki T., Takeshita S., Eto K., Toyoizumi H., Sato T., Miyashita H. Use of cilostazol, a novel antiplatelet agent, in a post-Palmaz-Schatz stenting regimen. Am. J. Cardiol. 79:1997;1471.
28. Bryan A.J., Angelini G.D. The biology of saphenous vein graft occlusion: etiology and strategies for prevention. Curr. Opin. Cardiol. 9:1994;641.
29. Callow A.D. Molecular biology of graft occlusion. Curr. Opin. Cardiol. 10:1995;569.
30. Indolfi C., Avvedimento E.V., Di Lorenzo E., Esposito G., Rapacciuolo A., Giuliano P., Grieco D., Cavuto L., Stingone A.M., Ciullo I., Condorelli G., Chiariello M. Activation of cAMP-PKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury. Nature Med. 3:1997;775.